Get the Stockscreener App
1.97
1.03%
0.02
Fractyl Health Inc stock is traded at $1.97, with a volume of 50,041.
It is up +1.03% in the last 24 hours and up +16.57% over the past month.
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
See More
Previous Close:
$1.95
Open:
$1.93
24h Volume:
50,041
Relative Volume:
0.17
Market Cap:
$105.79M
Revenue:
-
Net Income/Loss:
$-56.85M
P/E Ratio:
-1.2636
EPS:
-1.559
Net Cash Flow:
-
1W Performance:
-13.22%
1M Performance:
+16.57%
6M Performance:
+3.68%
1Y Performance:
-63.38%
1-Day Range:
$1.91
$2.00
1-Week Range:
$1.91
$2.302
52-Week Range:
$0.873
$5.50
Fractyl Health Inc Stock (GUTS) Company Profile
Name
Fractyl Health Inc
Sector
Industry
Phone
781-902-8800
Address
3 VAN DE GRAAFF DRIVE, BURLINGTON
Compare GUTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
1.975 | 105.79M | 0 | -56.85M | 0 | -1.559 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.31 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
515.23 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.67 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.10 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.00 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-24 | Initiated | Evercore ISI | Outperform |
| Feb-27-24 | Initiated | BofA Securities | Buy |
| Feb-27-24 | Initiated | Morgan Stanley | Overweight |
Fractyl Health Inc Stock (GUTS) Latest News
Fractyl Health Obtains 2 US Patents for Duodenal Resurfacing - marketscreener.com
Fractyl Health receives two new patents for duodenal resurfacing tech By Investing.com - Investing.com Nigeria
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New - Bluefield Daily Telegraph
Fractyl Health Secures 2 Key Patents for Breakthrough Metabolic Disease Treatment | GUTS Stock News - Stock Titan
Bank of America Corp DE Sells 26,192 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Fractyl Health to Present New Preclinical Data from its - GlobeNewswire
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene ... - Eagle-Tribune
Fractyl Reveals Single-Dose Gene Therapy Data for Diabetes Treatment at ADA 2025 | GUTS Stock News - Stock Titan
Jane Street Group LLC Boosts Stake in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Nuveen Asset Management LLC Has $150,000 Stock Position in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Fractyl, Bariendo developing off-ramp for post-GLP-1 maintenance - BioWorld MedTech
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide - marketscreener.com
Fractyl Health and Bariendo Sign Letter of Intent to - GlobeNewswire
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide - Yahoo Finance
Northern Trust Corp Sells 9,467 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Fractyl Health, Inc. (NASDAQ:GUTS) Shares Sold by Citadel Advisors LLC - Defense World
Transcript : Fractyl Health, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 05 - marketscreener.com
Fractyl Health submits first module of its CTA in Europe for RJVA-001 - TipRanks
Fractyl Health advances gene therapy for diabetes treatment By Investing.com - Investing.com South Africa
Fractyl Health advances gene therapy for diabetes treatment - Investing.com Australia
Fractyl Health Submits Clinical Trial Application in Europe - TipRanks
Fractyl Health Submits First Module of EU Trial Application for Gene Therapy RJVA-001 - marketscreener.com
Fractyl Health Unveils Promising Gene Therapy Data - TipRanks
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial ... - Eagle-Tribune
Fractyl Health Advances Rejuva® Gene Therapy Platform with - GlobeNewswire
Breakthrough One-Time Gene Therapy Could Replace Daily Diabetes Drugs, Heads to European Trials - Stock Titan
China On the March as U.S. Investors Plough Back in After Tariff Tension - The Globe and Mail
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 - The Manila Times
Fractyl Health Announces Promising Preclinical Data for RJVA-001, a Novel Gene Therapy for Type 2 Diabetes at ASGCT 2025 - Nasdaq
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data ... - Eagle-Tribune
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic - GlobeNewswire
Revolutionary One-Time GLP-1 Gene Therapy Achieves Powerful Diabetes Control with 5X Lower Side Effect Risk - Stock Titan
Prediction: Taiwan Semiconductor Stock Could Surge by 129% in the Next 5 Years - The Globe and Mail
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise - The Globe and Mail
Analysts and Institutions Continue to Bet Big on Alphabet - The Globe and Mail
16,400 Shares in Fractyl Health, Inc. (NASDAQ:GUTS) Bought by Raymond James Financial Inc. - Defense World
Fractyl signals accelerated enrollment for REMAIN-1 study while advancing Rejuva clinical milestones - MSN
Forge Biologics Inks AAV Development and cGMP Manufacturing Deal with Fractyl Health - Genetic Engineering and Biotechnology News
Fractyl Health Partners with Forge for Rejuva Gene Therapy Development - Contract Pharma
Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases - Business Wire
1 Super Stock Down 76% You'll Regret Not Buying on the Dip in 2025 - The Globe and Mail
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Fractyl Health Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Fractyl Health’s Q1 2025 shows rising R&D costs - Investing.com Nigeria
FRACTYL HEALTH, INC. SEC 10-Q Report - TradingView
Should You Buy Roku Stock Now With $500 and Hold for 10 Years? - The Globe and Mail
These High-Growth Stocks Were Down Over 50% This Year. Is It Time to Buy Them? - The Globe and Mail
Fractyl Health (GUTS) Expected to Announce Earnings on Tuesday - Defense World
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference - The Manila Times
Fractyl Health to Report First Quarter 2025 Financial - GlobeNewswire
Fractyl Health Inc Stock (GUTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fractyl Health Inc Stock (GUTS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barnes Kelly Ann | Director |
Mar 14 '25 |
Buy |
1.30 |
31,000 |
40,210 |
31,000 |
| SCHULMAN AMY W | Director |
Mar 13 '25 |
Buy |
1.17 |
8,550 |
9,964 |
8,550 |
| BRADLEY WILLIAM | Director |
Mar 13 '25 |
Buy |
1.26 |
16,129 |
20,358 |
16,129 |
| Conaway Samuel | Director |
Mar 13 '25 |
Buy |
1.17 |
8,550 |
9,964 |
8,550 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 31 '25 |
Option Exercise |
1.70 |
90,972 |
154,652 |
582,301 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 30 '25 |
Option Exercise |
1.70 |
20,948 |
35,612 |
512,277 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 31 '25 |
Sale |
1.82 |
90,972 |
165,205 |
491,329 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 30 '25 |
Sale |
1.95 |
20,948 |
40,798 |
491,329 |
| Caplan Jay David | President, Chief Product Off. |
Jan 31 '25 |
Option Exercise |
1.70 |
22,346 |
37,988 |
175,890 |
| Caplan Jay David | President, Chief Product Off. |
Jan 30 '25 |
Option Exercise |
1.70 |
21,472 |
36,502 |
175,016 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):